FREED of Opioids Act
3/13/2024, 5:16 PMSummary of Bill S 2737
The FREED of Opioids Act, also known as Bill 118 s 2737, is a piece of legislation currently being considered by the US Congress. The main goal of this bill is to address the opioid crisis in the United States by implementing various measures to combat the misuse and overprescription of opioids.One key provision of the FREED of Opioids Act is the establishment of a national prescription drug monitoring program. This program would require healthcare providers to check a centralized database before prescribing opioids to ensure that patients are not receiving multiple prescriptions from different doctors, a practice known as "doctor shopping."
Additionally, the bill includes provisions to increase funding for addiction treatment and recovery programs, as well as for law enforcement efforts to combat the illegal distribution of opioids. It also aims to improve access to non-opioid pain management alternatives for patients. Overall, the FREED of Opioids Act seeks to address the opioid crisis from multiple angles, including prevention, treatment, and enforcement. Supporters of the bill argue that it is a comprehensive approach to tackling this complex issue, while critics may raise concerns about the potential impact on healthcare providers and patients.
Congressional Summary of S 2737
FDA Review of Efficacy of EERW Double-Blinds of Opioids Act or the FREED of Opioids Act
This bill requires the Food and Drug Administration (FDA) to take certain actions to determine whether to permit the use of a certain methodology for drug clinical trials.
Specifically, the FDA must seek to contract with the National Academy of Sciences (NAS) for the NAS to conduct a study on the effectiveness of using enriched enrollment randomized withdrawal methodology in demonstrating the efficacy of opioid drugs in treating chronic pain.
The FDA must also convene a meeting of two specified FDA advisory committees to review the NAS study, vote on whether to permit the use of this methodology in drug clinical trials, and review the appropriateness of labeling on approved opioid drugs in relation to this methodology.
Read the Full Bill
Current Status of Bill S 2737
Bill S 2737 is currently in the status of Bill Introduced since September 7, 2023. Bill S 2737 was introduced during Congress 118 and was introduced to the Senate on September 7, 2023. Bill S 2737's most recent activity was Read twice and referred to the Committee on Health, Education, Labor, and Pensions. as of September 7, 2023Bipartisan Support of Bill S 2737
Total Number of Sponsors
1Democrat Sponsors
1Republican Sponsors
0Unaffiliated Sponsors
0Total Number of Cosponsors
2Democrat Cosponsors
0Republican Cosponsors
2Unaffiliated Cosponsors
0Policy Area and Potential Impact of Bill S 2737
Primary Policy Focus
HealthAlternate Title(s) of Bill S 2737
FREED of Opioids ActFREED of Opioids ActFDA Review of Efficacy of EERW Double-Blinds of Opioids ActA bill to require the Food and Drug Administration to determine whether to permit the use of enriched enrollment randomized withdrawal methodology with respect to clinical trials.Comments
Most relevant
Sponsors and Cosponsors of S 2737
Latest Bills
Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to "Review of Final Rule Reclassification of Major Sources as Area Sources Under Section 112 of the Clean Air Act".
Bill HJRES 79April 8, 2025
Medicare Dental, Vision, and Hearing Benefit Act of 2025
Bill HR 2045April 8, 2025
Lactation Spaces for Veteran Moms Act
Bill HR 1646April 8, 2025
DMEPOS Relief Act of 2025
Bill HR 2005April 8, 2025
Physicians for Underserved Areas Act
Bill S 1044April 8, 2025
NICS Data Reporting Act
Bill HR 2267April 8, 2025
Providing for consideration of the joint resolution (S.J. Res. 18) disapproving the rule submitted by the Bureau of Consumer Financial Protection relating to "Overdraft Lending: Very Large Financial Institutions"; providing for consideration of the joint resolution (S.J. Res. 28) disapproving the rule submitted by the Bureau of Consumer Financial Protection relating to "Defining Larger Participants of a Market for General-Use Digital Consumer Payment Applications"; providing for consideration of the bill (H.R. 1526) to amend title 28, United States Code, to limit the authority of district courts to provide injunctive relief, and for other purposes; providing for consideration of the bill (H.R. 22) to amend the National Voter Registration Act of 1993 to require proof of United States citizenship to register an individual to vote in elections for Federal office, and for other purposes; and for other purposes.
Bill HRES 294April 8, 2025
Providing for consideration of the joint resolution (H.J. Res. 25) providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Internal Revenue Service relating to "Gross Proceeds Reporting by Brokers That Regularly Provide Services Effectuating Digital Asset Sales"; providing for consideration of the bill (H.R. 1156) to amend the CARES Act to extend the statute of limitations for fraud under certain unemployment programs, and for other purposes; providing for consideration of the bill (H.R. 1968) making further continuing appropriations and other extensions for the fiscal year ending September 30, 2025, and for other purposes; and for other purposes.
Bill HRES 211April 8, 2025
SAVE Act
Bill HR 22April 8, 2025
A joint resolution disapproving the rule submitted by the Bureau of Consumer Financial Protection relating to "Overdraft Lending: Very Large Financial Institutions".
Bill SJRES 18April 8, 2025
SUPPORT for Patients and Communities Reauthorization Act
Bill S 3393March 5, 2024